Withanolide D
drugOn this page
Also known as Ajagandha wholeAmukkara in tamil wholeAngelica sinensisAngelica sinensis (oliv.) dielsAngelica sinensis rootAngelica sinensis wholeradixAngelicae sinensis radixAsgandh rootAsgandh wholeAshvagandba rootAshvagandba wholeAshvagandha wholeAshwaganda rootAshwaganda wholeAshwagandhaAshwagandha rootAshwagandha wholeChinese angelicaChinese angelica root
Summary
Withanolide D (CHEMBL4288984) is a phase-3 clinical-stage small-molecule antineoplastic agent; indicated across 5 conditions including amyotrophic lateral sclerosis and nasopharyngeal carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 5 conditions
- Clinical trials: 23
- Chemistry: 470.6 Da · C28H38O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4288984 |
| Name | Withanolide D |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 161671 |
| ChEBI | CHEBI:10041 |
| Molecular formula | C28H38O6 |
| Molecular weight | 470.6 |
| InChIKey | SASUFNRGCZMRFD-JCUIILOWSA-N |
SMILES: CC1=C(C(=O)O[C@H](C1)[C@@](C)([C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3C[C@@H]5[C@]6([C@@]4(C(=O)C=C[C@@H]6O)C)O5)C)O)C
IUPAC name: (1S,2R,6S,7R,9R,11S,12S,15S,16S)-15-[(1R)-1-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-4-en-3-one
ChEBI definition: A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 22 (the 4β,5β,6β,22R stereoisomer). Isolated from Tubocapsicum anomalum and Withania somnifera, it exhibits cytotoxic activity.
Pharmacological roles (ChEBI): antineoplastic agent.
Also known as: Ajagandha whole, Amukkara in tamil whole, Angelica sinensis, Angelica sinensis (oliv.) diels, Angelica sinensis root, Angelica sinensis whole, radix, Angelicae sinensis radix, Asgandh root, Asgandh whole, Ashvagandba root, Ashvagandba whole
Patent coverage: 33 distinct patent families (60 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Nuclear factor NF-kappa-B complex.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NFKB1 | 7.44 | IC50 | 36 | nM | CHEMBL_ACT_23248984 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| amyotrophic lateral sclerosis | 2 | MONDO:0004976 | MONDO:0004976 |
| nasopharyngeal carcinoma | 2 | MONDO:0015459 | MONDO:0015459 |
| periodontitis | 1 | MONDO:0005076 | EFO:0000649 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 23.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00199485 | PHASE4 | COMPLETED | Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer |
| NCT05840731 | PHASE4 | UNKNOWN | Role of Ashwagandha Extract (Capsule KSM-66 300 mg) in Improving Sexual Health in Healthy Men |
| NCT00710164 | PHASE2/PHASE3 | UNKNOWN | Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke |
| NCT02008981 | PHASE3 | COMPLETED | Effect of Herbal Products on Platelet Function and Clotting |
| NCT05610735 | PHASE1/PHASE2 | RECRUITING | Combination Therapy for Recurrent Ovarian Cancer |
| NCT00689195 | PHASE1/PHASE2 | UNKNOWN | Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma |
| NCT03533972 | PHASE1/PHASE2 | COMPLETED | Effect of Ashwagandha on Salivary Antioxidant and Serum c Reactive Protein in Chronic Generalized Periodontitis |
| NCT04092647 | PHASE2 | UNKNOWN | Ashwagandha for Cognitive Dysfunction |
| NCT05031351 | PHASE2 | UNKNOWN | NF-κB Inhibition in Amyotrophic Lateral Sclerosis |
| NCT05430685 | PHASE2 | COMPLETED | The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students |
| NCT07575516 | PHASE2 | COMPLETED | Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone |
| NCT00817752 | PHASE1 | COMPLETED | Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation |
| NCT06793891 | Not specified | RECRUITING | Effects of Ashwagandha Extract on Stress Levels |
| NCT07151261 | Not specified | ACTIVE_NOT_RECRUITING | Ashwagandha for Nighttime Waking |
| NCT07210229 | Not specified | NOT_YET_RECRUITING | The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial |
| NCT03596307 | Not specified | UNKNOWN | The Effects of Ashwagandha in Endurance Exercise Performance |
| NCT05831241 | Not specified | COMPLETED | Effects of Ashwagandha Extract (Capsule KSM-66 300 mg) on Sexual Health in Healthy Women |
| NCT06264986 | Not specified | COMPLETED | The Effects of Ashwagandha (Withania Somnifera) Supplementation on Exercise Performance in Female Footballers |
| NCT06676605 | Not specified | COMPLETED | Impact of Ashwagandha in Obesity Parameters from Mexican Adults |
| NCT06900569 | Not specified | COMPLETED | Ashwagandha Supplementation for Prevention of Muscle Damage |
| NCT07041853 | Not specified | COMPLETED | The Effects of KSM-66 Ashwagandha Supplementation on Recovery and Muscle Strength in Academy Athletes |
| NCT07461402 | Not specified | COMPLETED | Plant Protein With Ashwagandha-Rhodiola for Sleep Quality |
| NCT07541157 | Not specified | COMPLETED | Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.